Comparing Ardent Health (NYSE:ARDT) and Pheton (NASDAQ:PTHL)

Ardent Health (NYSE:ARDT) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Ardent Health and Pheton, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardent Health	1	1	9	0	2.73
Pheton	0	0	0	0	0.00

Ardent Health currently has a consensus price target of $19.33, suggesting a potential upside of 45.10%. Given Ardent Health’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Ardent Health is more favorable than Pheton.

Earnings & Valuation

This table compares Ardent Health and Pheton”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardent Health	$5.97 billion	0.32	$210.34 million	$1.81	7.36
Pheton	$450,000.00	13.31	-$660,000.00	N/A	N/A

Ardent Health has higher revenue and earnings than Pheton.

Profitability

This table compares Ardent Health and Pheton’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ardent Health	4.11%	16.66%	5.18%
Pheton	N/A	N/A	N/A

Summary

Ardent Health beats Pheton on 8 of the 9 factors compared between the two stocks.

About Ardent Health

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.